Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.36
-0.26 (-0.71%)
At close: Sep 4, 2026, 4:00 PM EDT
37.19
+0.83 (2.28%)
After-hours: Sep 4, 2026, 7:59 PM EDT

Teva Pharmaceutical Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $41.6. The average 1-year stock price forecast is 14.41% higher than the current stock price, while the lowest is $33 (-9.24%) and the highest is $50 (+37.51%).

Price Target: $41.6 (+14.41%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$33$41.6$42$50
Change-9.24%+14.41%+15.51%+37.51%

Analyst Ratings

The average analyst rating for Teva Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy888777
Buy445554
Hold110001
Sell000000
Strong Sell000000
Total131313121212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Maintains
$42$48
BuyMaintains$42$48+32.01%Sep 4, 2026
Jefferies
Jefferies
Buy
Maintains
$40
BuyMaintains$40+10.01%Sep 3, 2026
Scotiabank
Scotiabank
Buy
Maintains
$40
BuyMaintains$40+10.01%Sep 3, 2026
Goldman Sachs
Goldman Sachs
Buy
Maintains
$50
BuyMaintains$50+37.51%Sep 3, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
$41$43
BuyReiterates$41$43+18.26%Sep 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
16.58B
from 17.26B
Decreased by -3.92%
Revenue Next Year
17.30B
from 16.58B
Increased by 4.36%
EPS This Year
n/a
EPS Next Year
n/a
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
15.88B14.93B15.85B16.54B17.26B16.58B
Revenue Growth
-4.69%-6.00%6.17%4.41%4.32%-3.92%
Gross Profit
7.59B6.97B7.65B8.06B8.94B8.94B
Gross Margin
47.83%46.72%48.25%48.74%51.79%53.92%
Operating Income
3.08B2.66B3.19B3.37B3.95B3.98B
Net Income
417.00M-2.45B-559.00M-1.64B1.41B1.44B
Free Cash Flow
2.31B2.90B3.30B2.62B2.03B2.19B
No. Analysts
-----9

Revenue Forecast

Revenue202620272028
High16.7B
Avg16.6B
Low16.4B

Revenue Growth

Revenue Growth202620272028
High
-3.3%
Avg
-3.9%
Low
-5.1%

EPS Forecast

EPS202620272028
High-
Avg-
Low-

EPS Growth

EPS Growth20272028
High-
Avg-
Low-